Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Neogenix Oncology announced today that Dr. Luis Diaz of The Johns Hopkins University Hospital will present data from Ensituximab, the company's novel, therapeutic antibody to treat pancreatic and colorectal cancers. The presentation is scheduled at the American Society of Clinical Oncology (ASCO) 2011 Gastrointestinal Cancers Symposium to be held January 20-22, 2011 at the Moscone Center in San Francisco, CA, USA.

19 Jan 2011

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN® versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

18 Jan 2011

Noninvasive radiofrequency fields and targeted gold nanoparticles effective in controlling pancreatic tumors

Kanzius Cancer Research Foundation announces research conducted in the Kanzius/Curley Lab at The University of Texas M.D. Anderson Cancer Center has been published in the December 2010 issue of the American Association of Cancer Research's Clinical Cancer Research journal.

14 Jan 2011

MGH researchers discover massive overexpression of DNA sequences in cancer cells

Massachusetts General Hospital Cancer Center researchers have discovered a previously unknown feature of common tumor cells - massive overexpression of certain DNA sequences that do not code for proteins.

14 Jan 2011

Research study to develop rapid, inexpensive blood screening test for early diagnosis of pancreatic cancer

A clinical research study to develop a rapid and inexpensive blood screening test for the early diagnosis of pancreatic cancer has been launched by Henry Ford Health System and the Barbara Ann Karmanos Cancer Institute.

14 Jan 2011

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen, Inc. today announced initiation of an open-label phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fatal lung disease for which there are no FDA-approved therapies.

13 Jan 2011

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib (formerly STA-9090) in patients with multiple myeloma.

13 Jan 2011

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

MedImmune, the global biologics unit of AstraZeneca PLC and Micromet, today announced the initiation of a Phase 1 trial of MEDI-565 in patients with advanced gastrointestinal cancers. MEDI-565 is a BiTE antibody designed to direct a patient's T cells, the body's most potent killer cells, against cancer cells that express carcinoembryonic antigen.

13 Jan 2011

Scientists find way to prevent early stage pancreatic cancer in research models

Cancer researchers at The Peggy and Charles Stephenson Oklahoma Cancer Center have found a way to stop early stage pancreatic cancer in research models - a result that has far-reaching implications in chemoprevention for high-risk patients.

12 Jan 2011

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.

10 Jan 2011

Infinity provides guidance on anticipated pipeline and business goals for 2011

Infinity Pharmaceuticals, Inc. today provided guidance on its anticipated pipeline and business goals for 2011. Infinity begins the year with a broad pipeline of four drug candidates in clinical development and a fifth expected to enter the clinic during the year. The company also enters 2011 with approximately $345 million in committed capital.

7 Jan 2011

Biomarker study yields diagnostic blood test candidate for detection of Alzheimer's disease

OPKO Health, Inc. today announced the publication of a biomarker study yielding its diagnostic blood test candidate for the detection of Alzheimer's disease.

7 Jan 2011

Researchers develop simple blood test to track Alzheimer's disease

Using a new technology that relies on thousands of synthetic molecules to fish for disease-specific antibodies, researchers have developed a potential method for detecting Alzheimer's disease with a simple blood test.

6 Jan 2011

Nanoparticles may help diagnose and treat pancreatic and ovarian cancer

The research - carried out by a group of five institutions, including Einstein, that comprise the Texas Center for Cancer Nanomedicine - could lead to novel ways to diagnose and treat pancreatic and ovarian cancer using nanoparticles.

4 Jan 2011

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

NCI grants U-M Cancer Center $10.7M for study of colorectal and pancreatic cancer

The University of Michigan Comprehensive Cancer Center has received a five-year $10.7 million grant from the National Cancer Institute to study colorectal and pancreatic cancer.

23 Dec 2010

New predictive medicine product for hereditary pancreatic and related cancers

Myriad Genetics, Inc. today announced the launch of PANEXIA™, a predictive medicine product for hereditary pancreatic and related cancers. PANEXIA is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. PANEXIA, Myriad's ninth molecular diagnostic product, is the second product launched by the Company this year.

21 Dec 2010

Scientists discover potential strategy for pancreatic cancer therapy

By determining what goes missing in human cells when the gene that is most commonly mutated in pancreatic cancer gets turned on, Johns Hopkins scientists have discovered a potential strategy for therapy.

15 Dec 2010

Infinity extends global strategic alliance with Mundipharma for development, commercialization of IPI-926

Infinity Pharmaceuticals, Inc. today announced the extension of its global strategic alliance with Mundipharma International Corporation Limited to develop and commercialize IPI-926, Infinity's novel Smoothened antagonist, as well as development candidates arising from Infinity's phosphoinositol-3-kinase (PI3K) and discovery programs.

13 Dec 2010

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.

10 Dec 2010

Pancreatic Cancer News and Research

Further Reading

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Noninvasive radiofrequency fields and targeted gold nanoparticles effective in controlling pancreatic tumors

MGH researchers discover massive overexpression of DNA sequences in cancer cells

Research study to develop rapid, inexpensive blood screening test for early diagnosis of pancreatic cancer

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

Scientists find way to prevent early stage pancreatic cancer in research models

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Infinity provides guidance on anticipated pipeline and business goals for 2011

Biomarker study yields diagnostic blood test candidate for detection of Alzheimer's disease

Researchers develop simple blood test to track Alzheimer's disease

Nanoparticles may help diagnose and treat pancreatic and ovarian cancer

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

NCI grants U-M Cancer Center $10.7M for study of colorectal and pancreatic cancer

New predictive medicine product for hereditary pancreatic and related cancers

Scientists discover potential strategy for pancreatic cancer therapy

Infinity extends global strategic alliance with Mundipharma for development, commercialization of IPI-926

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News